Replies to post #305503 on Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

I think it is your thinking that is askew if you think I have said this somewhere recently:

" But you just keep seeing Brilacidin and Kevetrin as run of the mill drugs (or less, as you basically said Kevetrin wasn't worth squat)."

Please support your assertion.


BTW, the R01 grant success rate was 20% from my link:

https://nexus.od.nih.gov/all/2020/05/05/extramural-investments-in-research-fy-2019-by-the-numbers/

I think brilacidin's chances are much better and that they will get more than $0.5M average. I've already said as much.